UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Abatacept for lupus nephritis: Alternative definitions of complete response support conflicting conclusions

Arthritis & rheumatology (Hoboken, N.J.), 2012-11, Vol.64 (11), p.3660-3665

2012

Volltextzugriff (PDF)

Efficacy and Safety of Abatacept in Lupus Nephritis: A Twelve‐Month, Randomized, Double‐Blind Study

Arthritis & rheumatology (Hoboken, N.J.), 2014-02, Vol.66 (2), p.379-389

2014

Volltextzugriff (PDF)

M281, an Anti‐FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First‐in‐Human Study

Clinical pharmacology and therapeutics, 2019-04, Vol.105 (4), p.1031-1039

2019

Volltextzugriff (PDF)

Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factor

Arthritis research & therapy, 2019-10, Vol.21 (1), p.216-216, Article 216

2019

Volltextzugriff (PDF)

First‐in‐human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN‐101, a dual CD28/ICOS antagonist, in healthy adult subjects

Clinical and translational science, 2021-07, Vol.14 (4), p.1314-1326

2021

Volltextzugriff (PDF)

Comparison of Alternative Primary Outcome Measures for Use in Lupus Nephritis Clinical Trials

Arthritis & rheumatology (Hoboken, N.J.), 2013-06, Vol.65 (6), p.1586-1591

2013

Volltextzugriff (PDF)

Peginterferon Lambda-1a, a New Therapeutic for Hepatitis C Infection, from Bench to Clinic

Journal of clinical and translational hepatology, 2013-12, Vol.1 (2), p.116-124

2013

Volltextzugriff (PDF)

An Open Label Study of Alpn-101, a First-in-Class Dual CD28/ICOS Antagonist, in Subjects with Steroid-Resistant or Steroid-Refractory Acute Graft Versus Host Disease (aGVHD)

Blood, 2019-11, Vol.134 (Supplement_1), p.372-372

2019

Volltextzugriff (PDF)

Early Restriction of the Human Antibody Repertoire

Science (American Association for the Advancement of Science), 1987-11, Vol.238 (4828), p.791-793

1987

Volltextzugriff (PDF)

Rofecoxib

Expert opinion on pharmacotherapy, 2000-07, Vol.1 (5), p.1053-1066

2000

Volltextzugriff (PDF)

Development of the Antibody Repertoire as Revealed by Single‐Cell PCR of FACS‐Sorted B‐Cell Subsetsa

Annals of the New York Academy of Sciences, 1995-09, Vol.764 (1), p.224-227

1995

Volltextzugriff (PDF)

The structural basis of germline-encoded VH3 immunoglobulin binding to staphylococcal protein A

The Journal of experimental medicine, 1993-07, Vol.178 (1), p.331-336

1993

Volltextzugriff (PDF)

Structure and evolution of mammalian VH families

International immunology, 1990-01, Vol.2 (1), p.41-50

1990

Volltextzugriff (PDF)

PHARMACOLOGY AND PHARMACOKINETICS OF METHOTREXATE IN RHEUMATIC DISEASE

Rheumatic diseases clinics of North America, 1997-11, Vol.23 (4), p.757-778

1997

Volltextzugriff (PDF)

Development of the Antibody Repertoire as Revealed by Single-Cell PCR of FACS-Sorted B-Cell Subsets

Annals of the New York Academy of Sciences, 1995-09, Vol.764 (1), p.224-227

1995

Volltextzugriff (PDF)

Autoantibodies and the Fetal Antibody Repertoire

International reviews of immunology, 1990, Vol.5 (3-4), p.215-229

1990

Volltextzugriff (PDF)

Structure and evolution of mammalian V H families

International immunology, 1990, Vol.2 (1), p.41-50

1990

Volltextzugriff (PDF)

A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection

Journal of hepatology, 2014-12, Vol.61 (6), p.1238-1246

2014

Volltextzugriff (PDF)

Abstract CT245: NEON-1: A first-in-human phase I open-label study of ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT245-CT245

2020

Volltextzugriff (PDF)

Abstract CT213: NEON-1: a first-in-human phase I open-label study of ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.CT213-CT213

2021

Volltextzugriff (PDF)

First-in-human dose escalation of ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.2547-2547

2021

Volltextzugriff (PDF)

Alpn-101 (ICOSL vIgD-Fc), a Dual Antagonist of the ICOS and CD28 Costimulatory Pathways, for Treatment of Steroid Refractory Acute GVHD (aGVHD): Case Report

Transplantation and cellular therapy, 2021-03, Vol.27 (3), p.S265-S266

2021

Volltextzugriff (PDF)

Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis

Arthritis research, 2001-01, Vol.3 (4), p.247-252, Article 247

2001

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(24)

Sprache

Englisch
(24)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(13)
Science & Technology
(12)
Life Sciences & Biomedicine
(11)
Female
(7)
Male
(6)
Adult
(5)
Animals
(5)
Double-Blind Method
(5)
Genes, Immunoglobulin
(5)
Immunoglobulin Heavy Chains - Genetics
(5)
Immunoglobulin Variable Region - Genetics
(5)
Rheumatology
(5)
Treatment Outcome
(5)
Base Sequence
(4)
Dose-Response Relationship, Drug
(4)
Lupus
(4)
Abatacept
(3)
Amino Acid Sequence
(3)
Analysis
(3)
Antibodies
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Abatacept for lupus nephritis: Alternative definitions of complete response support conflicting conclusions

Efficacy and Safety of Abatacept in Lupus Nephritis: A Twelve‐Month, Randomized, Double‐Blind Study

M281, an Anti‐FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First‐in‐Human Study

Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factor

First‐in‐human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN‐101, a dual CD28/ICOS antagonist, in healthy adult subjects

Comparison of Alternative Primary Outcome Measures for Use in Lupus Nephritis Clinical Trials

Peginterferon Lambda-1a, a New Therapeutic for Hepatitis C Infection, from Bench to Clinic

An Open Label Study of Alpn-101, a First-in-Class Dual CD28/ICOS Antagonist, in Subjects with Steroid-Resistant or Steroid-Refractory Acute Graft Versus Host Disease (aGVHD)

Early Restriction of the Human Antibody Repertoire

Rofecoxib

M281: A Therapeutic Anti-FcRn Blocking Antibody for Rapid Clearance of IgG and IgG Autoantibodies in Immune Cytopenias and Other Auto/Allo-Immune Disease

Development of the Antibody Repertoire as Revealed by Single‐Cell PCR of FACS‐Sorted B‐Cell Subsetsa

The structural basis of germline-encoded VH3 immunoglobulin binding to staphylococcal protein A

Structure and evolution of mammalian VH families

PHARMACOLOGY AND PHARMACOKINETICS OF METHOTREXATE IN RHEUMATIC DISEASE

Development of the Antibody Repertoire as Revealed by Single-Cell PCR of FACS-Sorted B-Cell Subsets

Autoantibodies and the Fetal Antibody Repertoire

Structure and evolution of mammalian V H families

A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection

Abstract CT245: NEON-1: A first-in-human phase I open-label study of ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies

Abstract CT213: NEON-1: a first-in-human phase I open-label study of ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies

First-in-human dose escalation of ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies

Alpn-101 (ICOSL vIgD-Fc), a Dual Antagonist of the ICOS and CD28 Costimulatory Pathways, for Treatment of Steroid Refractory Acute GVHD (aGVHD): Case Report

Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis

Suchergebnisse filtern